Screening services for pre-clinical development of neuro-pharmaceuticals and safety pharmacology

Functional screening procedures with primary neuronal network cultures

NeuroProof's advanced neurochip technology combines in a unique way brain-region specific primary network co-cultures, consisting of the in-vivo-like neuronal and glial cell populations, with modern multichannel recording techniques and sophisticated data analysis e.g. pattern recognition.

NeuroProof GmbH offers screening services for drug development toward compound profiling by analyzing and clarifying compounds complex modes of action on the basis of functional changes of neuronal network activity.

The effect of potential drug candidates on the CNS and possible neuro-toxic effects can be predicted early by means of these results. Thus it is possible to considerably accelerate the preclinical development of CNS drugs and to cut down the attrition rate.

Brain-region specific nervous tissue taken from fetal mice is physiologically accessible during differentiation and up to several months after maturation. MEA-neurochips simultaneously record multiple spike train patterns of action potentials of a multitude of single neurons, connected in a complex network. Proprietary procedures of pattern recognition are applied for data analysis. Thus, the effect of CNS drug candidates can be examined directly, which was not possible before.